



2Q 2021 Financial results

2Q 2021

Worldwide sales
\$11.4 billion

GAAP EPS
\$0.48

Non-GAAP EPS
\$1.31

2021 Continuing operations financial outlook

Expects full-year 2021 sales growth of 12% to 14%; narrows and raises estimated full-year 2021 revenue range to be between \$46.4 billion and \$47.4 billion, including a positive impact from foreign exchange of less than 2%

Expects full-year 2021 GAAP EPS to be between \$4.24 and \$4.34; expects full-year 2021 Non-GAAP EPS to be between \$5.47 and \$5.57, including a positive impact from foreign exchange of approximately 2%

Key growth drivers

Oncology

KEYTRUDA®
(pembrolizumab) Injection 100 mg

Higher sales and continued uptake



Vaccines

GARDASIL®
[Human Papillomavirus Quadrivalent
(Types 6, 11, 16, and 18) Vaccine, Recombinant]

+

GARDASIL® 9
[Human Papillomavirus
9-valent Vaccine, Recombinant]

Growth driven by higher demand in the U.S. and China

Hospital Acute Care

bridion®
(sugammadex) Injection 100 mg/mL*

Higher demand globally and pandemic recovery

Animal Health



Higher global demand in companion animal and livestock products, including Animal Health Intelligence products



“We are encouraged by the strong momentum of our underlying business led by our key growth drivers as the impact of the pandemic on our performance lessens.

We are confident that we will deliver sustained long-term growth and value creation enabled by our strengthening discovery research engine and by working with increased speed, urgency and agility to accelerate the delivery of our innovations to the patients who depend on them.”

Rob Davis
CEO and President

Creating long-term value for patients, employees and shareholders

See investors.merck.com for Merck's full 2Q earnings release issued July 29, 2021, the associated webcast presentation, forward-looking statement, definitions of non-GAAP measures and reconciliations to the most closely related GAAP measure.